Harding Jane E, Wilson Jess, Brown Julie
Liggins Institute, The University of Auckland, Auckland, New Zealand, 1001.
Cochrane Database Syst Rev. 2017 Feb 26;2(2):CD003310. doi: 10.1002/14651858.CD003310.pub2.
Preterm infants are born with low skeletal stores of calcium and phosphorus. Preterm human milk provides insufficient calcium and phosphorus to meet the estimated needs of preterm infants for adequate growth. Supplementation of human milk with calcium and phosphorus may improve growth and development of preterm infants.
To determine whether addition of calcium and phosphorus supplements to human milk leads to improved growth and bone metabolism of preterm infants without significant adverse effects.
We used the standard search strategy of the Cochrane Neonatal Review Group to search the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 3), MEDLINE via PubMed (1966 to 14 April 2016), Embase (1980 to 14 April 2016) and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 14 April 2016). We also searched clinical trials databases (11 May 2016) and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials.
Randomised and quasi-randomised trials comparing supplementation of human milk with calcium and/or phosphorus versus no supplementation in hospitalised preterm infants were eligible for inclusion in this review.
Two review authors (JB, JW) independently extracted data and assessed trial quality using standard methods of the Cochrane Neonatal Review Group. We reported dichotomous data as risk ratios (RRs) and continuous data as mean differences (MDs) with 95% confidence intervals (CIs). We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence.
This is an update of a 2001 review that identified no eligible trials. One trial including 40 infants met the inclusion criteria for this review. Using GRADE criteria, we judged the quality of the evidence as low owing to risk of bias (inadequate reporting of methods of randomisation, allocation concealment and/or blinding) and imprecision (wide confidence intervals and data from a single small trial). We found no evidence of a difference between calcium and phosphorus supplementation versus no supplementation for neonatal growth outcomes (weight, length, head circumference) at any time point reported (two, four or six weeks postnatal age). At six weeks postnatal age, supplementation with calcium/phosphorus was associated with a decrease in serum alkaline phosphatase concentration (MD -56.85 IU/L, 95% CI -101.27 to -12.43; one randomised controlled trial (RCT); n = 40 infants). Investigators provided no data on growth at 12 to 18 months, neonatal fractures, feed intolerance, breastfeeding or any of the prespecified childhood outcomes for this review (fractures, growth, neurodevelopmental outcomes).
AUTHORS' CONCLUSIONS: We identified one small trial including only 40 infants that compared supplementation of human milk with calcium and phosphorus versus no supplementation in hospitalised preterm infants. We judged the evidence to be of low quality and found no evidence of differences between groups for clinically important outcomes including growth and fractures. Although serum alkaline phosphatase concentration was reduced in the group receiving supplementation at six weeks postnatal age, this difference is unlikely to be of clinical significance. We conclude that evidence is insufficient to determine whether benefit or harm ensues when human milk is supplemented with calcium and/or phosphorus for the hospitalised preterm infant. We see no advantage of conducting further trials of this intervention because with the advent of multi-component human milk fortifier, supplementation of human milk with calcium and/or phosphorus alone is no longer common practice. Future trials should consider assessing effects of multi-component fortifiers with different mineral compositions on clinically important outcomes during the neonatal period and in later childhood.
早产儿出生时钙和磷的骨骼储备较低。早产母乳提供的钙和磷不足以满足早产儿充分生长的估计需求。在母乳中添加钙和磷可能会改善早产儿的生长发育。
确定在母乳中添加钙和磷补充剂是否能改善早产儿的生长和骨骼代谢,且无明显不良反应。
我们采用Cochrane新生儿综述小组的标准检索策略,检索Cochrane对照试验中心注册库(CENTRAL;2016年第3期)、通过PubMed检索MEDLINE(1966年至2016年4月14日)、Embase(1980年至2016年4月14日)以及护理和联合健康文献累积索引(CINAHL;1982年至2016年4月14日)。我们还检索了临床试验数据库(2016年5月11日)以及检索到的随机对照试验和半随机试验文章的参考文献列表。
比较住院早产儿母乳添加钙和/或磷与不添加的随机和半随机试验符合本综述的纳入标准。
两位综述作者(JB,JW)独立提取数据,并使用Cochrane新生儿综述小组的标准方法评估试验质量。我们将二分数据报告为风险比(RRs),连续数据报告为平均差(MDs),并给出95%置信区间(CIs)。我们采用推荐分级评估、制定与评价(GRADE)方法评估证据质量。
这是对2001年一篇综述的更新,该综述未识别出符合条件的试验。一项纳入40名婴儿的试验符合本综述的纳入标准。根据GRADE标准,由于存在偏倚风险(随机化方法、分配隐藏和/或盲法报告不充分)和不精确性(置信区间宽且数据来自单个小型试验),我们将证据质量判定为低。在报告的任何时间点(出生后两周、四周或六周),我们未发现钙和磷补充组与未补充组在新生儿生长结局(体重、身长、头围)方面存在差异的证据。在出生后六周时,补充钙/磷与血清碱性磷酸酶浓度降低相关(平均差 -56.85 IU/L,95%置信区间 -101.27至 -12.43;一项随机对照试验(RCT);n = 40名婴儿)。研究人员未提供12至18个月时的生长情况、新生儿骨折、喂养不耐受、母乳喂养或本综述预先设定的任何儿童期结局(骨折、生长、神经发育结局)的数据。
我们识别出一项仅纳入40名婴儿的小型试验,该试验比较了住院早产儿母乳添加钙和磷与不添加的情况。我们判定证据质量低,且未发现两组在包括生长和骨折等重要临床结局方面存在差异的证据。尽管出生后六周时补充组的血清碱性磷酸酶浓度有所降低,但这种差异不太可能具有临床意义。我们得出结论,证据不足以确定住院早产儿母乳添加钙和/或磷是有益还是有害。我们认为进行该干预的进一步试验没有优势,因为随着多成分母乳强化剂的出现,仅在母乳中添加钙和/或磷已不再是常见做法。未来的试验应考虑评估不同矿物质成分的多成分强化剂对新生儿期及儿童后期重要临床结局的影响。